[Federal Register Volume 91, Number 46 (Tuesday, March 10, 2026)]
[Notices]
[Pages 11555-11556]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2026-04664]



[[Page 11555]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-D-0611]


New and Revised Draft Q&As on Biosimilar Development and the 
Biologics Price Competition and Innovation Act; Draft Guidance for 
Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is 
announcing the availability of a revised draft guidance for industry 
entitled ``New and Revised Draft Q&As on Biosimilar Development and the 
BPCI Act (Revision 4).'' The question and answer (Q&A) format is 
intended to inform prospective applicants and facilitate the 
development of proposed biosimilar products and proposed 
interchangeable biosimilar products, as well as describe FDA's proposed 
interpretation of certain statutory requirements related to the 
abbreviated licensure pathway for biological products added by the 
Biologics Price Competition and Innovation Act of 2009 (BPCI Act). This 
draft guidance revises and replaces the draft guidance for industry 
entitled ``New and Revised Draft Q&As on Biosimilar Development and the 
BPCI Act (Revision 3)'' issued September 17, 2021 to provide certain 
revisions to Q&As I.8, I.10, and I.19, which have been withdrawn from 
the final guidance entitled ``Questions and Answers on Biosimilar 
Development and the BPCI Act'' issued September 20, 2021.

DATES: Submit either electronic or written comments on the draft 
guidance by May 11, 2026 to ensure that the Agency considers your 
comment on this draft guidance before it begins work on the final 
version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as 
follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2011-D-0611 for ``New and Revised Draft Q&As on Biosimilar 
Development and the BPCI Act (Revision 4).'' Received comments will be 
placed in the docket and, except for those submitted as ``Confidential 
Submissions,'' publicly viewable at https://www.regulations.gov or at 
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through 
Friday, 240-402-7500.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852, 240-402-7500.
    You may submit comments on any guidance at any time (see 21 CFR 
10.115(g)(5)).
    Submit written requests for single copies of the draft guidance to 
the Division of Drug Information, Center for Drug Evaluation and 
Research, Food and Drug Administration, 10001 New Hampshire Ave., 
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. The draft 
guidance may also be obtained by mail by calling CBER at 1-800-835-4709 
or 240-402-8010 or emailing [email protected]. Send one 
self-addressed adhesive label to assist that office in processing your 
requests. See the SUPPLEMENTARY INFORMATION section for electronic 
access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Mustafa Unlu, Center for Drug 
Evaluation and Research (HF-22), Food and Drug Administration, 10903 
New Hampshire Ave., Bldg. 22, Rm. 1139, Silver Spring, MD 20993-0001, 
301-796-3396, [email protected]; or Philip 
Kurs, Center for Biologics Evaluation and Research, Food and Drug 
Administration, 240-402-7911.

SUPPLEMENTARY INFORMATION:

[[Page 11556]]

I. Background

    FDA is announcing the availability of a draft guidance for industry 
entitled ``New and Revised Draft Q&As on Biosimilar Development and the 
BPCI Act (Revision 4).'' The BPCI Act amended the Public Health Service 
Act (PHS Act) and other statutes to create an abbreviated licensure 
pathway in section 351(k) of the PHS Act (42 U.S.C. 262(k)) for 
biological products shown to be biosimilar to, or interchangeable with, 
an FDA-licensed biological reference product (see sections 7001 through 
7003 of the Patient Protection and Affordable Care Act (Pub. L. 111-
148)). FDA's view is that guidance for industry that provides answers 
to commonly asked questions regarding FDA's interpretation of the BPCI 
Act will enhance transparency and facilitate the development and 
approval of biosimilar and interchangeable products.
    This draft guidance is a companion to the final guidance for 
industry issued in September 2021 entitled ``Questions and Answers on 
Biosimilar Development and the BPCI Act.'' In this pair of guidance 
documents, FDA issues each Q&A in draft form in a draft guidance, 
receives comments on the draft Q&A and, as appropriate, moves the Q&A 
to the final guidance after reviewing comments and incorporating 
suggested changes to the Q&A. A Q&A that was previously in the final 
guidance may be withdrawn and moved to a draft guidance if FDA 
determines that the Q&A should be revised in some respect and reissued 
in a revised draft Q&A for comment. Furthermore, a Q&A also may be 
withdrawn and removed from a Q&A guidance if, for instance, the 
concept(s) addressed by the Q&A is addressed, or would be addressed 
more appropriately, in a different FDA guidance document.
    This draft guidance contains Q&As distributed for comment purposes 
only and includes proposed revisions to Q&As that appeared in previous 
versions of the final guidance documents. The final guidance contains 
Q&As that have been through the public comment process and reflects 
FDA's current thinking on the topics described. While these guidances 
have been revised over time, FDA has maintained the original numbering 
of the Q&As as they were published in the original versions of these 
guidances and subsequent revisions (available at https://www.regulations.gov/docket/FDA-2011-D-0611/document).
    This draft guidance contains revised versions of three Q&As (Q&A 
I.8, Q&A I.10, and Q&A I.19). The revised Q&A I.8 is now organized into 
two parts: Part ``a'' describes FDA's updated recommendations regarding 
how a clinical study (such as an assessment of pharmacokinetics (PK)) 
comparing the proposed biosimilar with a non-U.S.-licensed comparator 
product could address, in part, the requirements under section 
351(k)(2)(A) of the PHS Act and support a demonstration of 
biosimilarity to the U.S.-licensed reference product in certain 
circumstances. Part ``a'' also identifies circumstances under which 
clinical data derived from a study using a non-U.S.-licensed comparator 
product may be acceptable. Part ``b'' elaborates on recommendations 
regarding the nature and extent of comparative analytical data between 
the non-U.S.-licensed comparator product and the U.S.-licensed 
reference product for purposes of the comparative analytical 
assessment. FDA is specifically requesting public comment on the 
utility of an analytical comparison between the proposed biosimilar 
product and the non-U.S.-licensed comparator product as part of the 
scientific justification to support the relevance of clinical data with 
a non-U.S.-licensed comparator product to a demonstration of 
biosimilarity to the U.S.-licensed reference product.
    Additionally, minor updates were made to Q&As I.10 and Q&A I.19 for 
clarity and to align with revised Q&A I.8. FDA's intent is that Part 
``a'' of Q&A I.8 may inform a future revised guidance for industry 
entitled ``Scientific Considerations in Demonstrating Biosimilarity to 
a Reference Product'' and Part ``b'' may inform future revisions to a 
guidance for industry entitled ``Development of Therapeutic Protein 
Biosimilars: Comparative Analytical Assessment and Other Quality-
Related Considerations'' as appropriate.
    At this time, FDA is also withdrawing Q&As I.8, I.10, and I.19 from 
the final guidance entitled ``Questions and Answers on Biosimilar 
Development and the BPCI Act'' issued September 20, 2021, and reissuing 
the final guidance (with certain updates to the introductory text) 
solely for the purpose of withdrawing these particular Q&As. The Agency 
continues to evaluate other Q&As in this final guidance as part of its 
efforts to further enhance efficiency in biosimilar development 
programs and intends to update any Q&As that may no longer reflect the 
Agency's current thinking, as appropriate.
    This draft guidance is being issued consistent with FDA's good 
guidance practices regulation (21 CFR 10.115). The draft guidance, when 
finalized, will represent the current thinking of FDA on ``New and 
Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 
4).'' It does not establish any rights for any person and is not 
binding on FDA or the public. You can use an alternative approach if it 
satisfies the requirements of the applicable statutes and regulations.
    As we develop final guidance on this topic, FDA will consider 
comments on costs or cost savings the guidance may generate, relevant 
for Executive Order 14192.

II. Paperwork Reduction Act of 1995

    While this guidance contains no collection of information, it does 
refer to previously approved FDA collections of information. The 
previously approved collections of information are subject to review by 
the Office of Management and Budget (OMB) under the Paperwork Reduction 
Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information 
in 21 CFR part 312 relating to submission of an investigational new 
drug application have been approved under OMB control number 0910-0014. 
The collections of information relating to the submission of a BLA 
under section 351(k) of the PHS Act, including the submission of data 
from comparative analytical assessments and a clinical study or studies 
(including the assessment of immunogenicity and PK or 
pharmacodynamics), that are sufficient to demonstrate safety, purity, 
and potency in one or more appropriate conditions of use for which the 
reference product is licensed, as well as formal meetings between FDA 
and sponsors, have been approved under OMB control number 0910-0718.

III. Electronic Access

    Persons with access to the internet may obtain the draft guidance 
at https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances, or https://www.regulations.gov.

Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2026-04664 Filed 3-9-26; 8:45 am]
BILLING CODE 4164-01-P